Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]

Mingming Sun; Leilei Li; Yujia Niu; Yingzhi Wang; Qi Yan; Fei Xie; Yaya Qiao; Jiaqi Song; Huanran Sun; Zhen Li; Sizhen Lai; Hongkai Chang; Han Zhang; Jiyan Wang; Chenxin Yang; Huifang Zhao; Junzhen Tan; Yanping Li; Shuangping Liu; Bin Lu; Min Liu; Guangyao Kong; Yujun Zhao; Chunze Zhang; Shu Hai Lin; Cheng Luo; Shuai Zhang; Changliang Shan

doi:10.1016/j.apsb.2025.02.006

Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]

Mingming Sun
, Leilei Li
, Yujia Niu
, Yingzhi Wang
, Qi Yan
, Fei Xie
, Yaya Qiao
, Jiaqi Song
, Huanran Sun
, Zhen Li
, Sizhen Lai
, Hongkai Chang
, Han Zhang
, Jiyan Wang
, Chenxin Yang
, Huifang Zhao
, Junzhen Tan
, Yanping Li
, Shuangping Liu
, Bin Lu

Min Liu, Guangyao Kong, Yujun Zhao, Chunze Zhang, Shu Hai Lin, Cheng Luo, Shuai Zhang, Changliang Shan

Nankai University
Jinan University
Xiamen University
Tianjin University of Traditional Chinese Medicine
Jining Medical College
Dalian University
University of South China
Wenzhou Medical University
Shandong Normal University
The Second Affiliated Hospital of Xi'an Jiaotong University
CAS - Shanghai Institute of Materia Medica

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret that a mistake occurred during the presentation of Supporting Information Fig. S1B, in which we put the wrong picture during submission. This correction does not significantly impact the findings and conclusions of the paper. The authors would like to assure readers that the corrected image does not alter the validity of the research. The original data of these figures have been provided to the Editorial Office, and the corresponding author can be contacted for original data access. The authors would like to apologize for any inconvenience caused. The corrected Fig. S1B appears below.[Figure

Original language	English
Pages (from-to)	2297-2299
Number of pages	3
Journal	Acta Pharmaceutica Sinica B
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.apsb.2025.02.006
State	Published - Apr 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.apsb.2025.02.006

Fingerprint

Dive into the research topics of 'Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]'. Together they form a unique fingerprint.

Cite this

Sun, M., Li, L., Niu, Y., Wang, Y., Yan, Q., Xie, F., Qiao, Y., Song, J., Sun, H., Li, Z., Lai, S., Chang, H., Zhang, H., Wang, J., Yang, C., Zhao, H., Tan, J., Li, Y., Liu, S., ... Shan, C. (2025). Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]. Acta Pharmaceutica Sinica B, 15(4), 2297-2299. https://doi.org/10.1016/j.apsb.2025.02.006

@article{49871d281ef74636968227d586d17923,

title = "Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]",

abstract = "The authors regret that a mistake occurred during the presentation of Supporting Information Fig. S1B, in which we put the wrong picture during submission. This correction does not significantly impact the findings and conclusions of the paper. The authors would like to assure readers that the corrected image does not alter the validity of the research. The original data of these figures have been provided to the Editorial Office, and the corresponding author can be contacted for original data access. The authors would like to apologize for any inconvenience caused. The corrected Fig. S1B appears below.[Figure",

author = "Mingming Sun and Leilei Li and Yujia Niu and Yingzhi Wang and Qi Yan and Fei Xie and Yaya Qiao and Jiaqi Song and Huanran Sun and Zhen Li and Sizhen Lai and Hongkai Chang and Han Zhang and Jiyan Wang and Chenxin Yang and Huifang Zhao and Junzhen Tan and Yanping Li and Shuangping Liu and Bin Lu and Min Liu and Guangyao Kong and Yujun Zhao and Chunze Zhang and Lin, \{Shu Hai\} and Cheng Luo and Shuai Zhang and Changliang Shan",

note = "Publisher Copyright: {\textcopyright} 2025",

year = "2025",

month = apr,

doi = "10.1016/j.apsb.2025.02.006",

language = "英语",

volume = "15",

pages = "2297--2299",

journal = "Acta Pharmaceutica Sinica B",

issn = "2211-3835",

publisher = "Chinese Academy of Medical Sciences",

number = "4",

}

Sun, M, Li, L, Niu, Y, Wang, Y, Yan, Q, Xie, F, Qiao, Y, Song, J, Sun, H, Li, Z, Lai, S, Chang, H, Zhang, H, Wang, J, Yang, C, Zhao, H, Tan, J, Li, Y, Liu, S, Lu, B, Liu, M, Kong, G, Zhao, Y, Zhang, C, Lin, SH, Luo, C, Zhang, S & Shan, C 2025, 'Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]', Acta Pharmaceutica Sinica B, vol. 15, no. 4, pp. 2297-2299. https://doi.org/10.1016/j.apsb.2025.02.006

Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]. / Sun, Mingming; Li, Leilei; Niu, Yujia et al.
In: Acta Pharmaceutica Sinica B, Vol. 15, No. 4, 04.2025, p. 2297-2299.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]

AU - Sun, Mingming

AU - Li, Leilei

AU - Niu, Yujia

AU - Wang, Yingzhi

AU - Yan, Qi

AU - Xie, Fei

AU - Qiao, Yaya

AU - Song, Jiaqi

AU - Sun, Huanran

AU - Li, Zhen

AU - Lai, Sizhen

AU - Chang, Hongkai

AU - Zhang, Han

AU - Wang, Jiyan

AU - Yang, Chenxin

AU - Zhao, Huifang

AU - Tan, Junzhen

AU - Li, Yanping

AU - Liu, Shuangping

AU - Lu, Bin

AU - Liu, Min

AU - Kong, Guangyao

AU - Zhao, Yujun

AU - Zhang, Chunze

AU - Lin, Shu Hai

AU - Luo, Cheng

AU - Zhang, Shuai

AU - Shan, Changliang

PY - 2025/4

Y1 - 2025/4

N2 - The authors regret that a mistake occurred during the presentation of Supporting Information Fig. S1B, in which we put the wrong picture during submission. This correction does not significantly impact the findings and conclusions of the paper. The authors would like to assure readers that the corrected image does not alter the validity of the research. The original data of these figures have been provided to the Editorial Office, and the corresponding author can be contacted for original data access. The authors would like to apologize for any inconvenience caused. The corrected Fig. S1B appears below.[Figure

AB - The authors regret that a mistake occurred during the presentation of Supporting Information Fig. S1B, in which we put the wrong picture during submission. This correction does not significantly impact the findings and conclusions of the paper. The authors would like to assure readers that the corrected image does not alter the validity of the research. The original data of these figures have been provided to the Editorial Office, and the corresponding author can be contacted for original data access. The authors would like to apologize for any inconvenience caused. The corrected Fig. S1B appears below.[Figure

UR - https://www.scopus.com/pages/publications/85219017956

U2 - 10.1016/j.apsb.2025.02.006

DO - 10.1016/j.apsb.2025.02.006

M3 - 评论/辩论

AN - SCOPUS:85219017956

SN - 2211-3835

VL - 15

SP - 2297

EP - 2299

JO - Acta Pharmaceutica Sinica B

JF - Acta Pharmaceutica Sinica B

IS - 4

ER -

Sun M, Li L, Niu Y, Wang Y, Yan Q, Xie F et al. Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]. Acta Pharmaceutica Sinica B. 2025 Apr;15(4):2297-2299. doi: 10.1016/j.apsb.2025.02.006

Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this